TipRanks

Notifications

CYCC Earnings this Week: How Will it Perform?

Cyclacel Pharmaceuticals (CYCC) is scheduled to report 2nd quarter earnings on 08/09/2023, after the market closes.

Regarding Q2 estimates, Wall Street analysts expect Cyclacel Pharmaceuticals to post earnings of -$0.50 per share. Last quarter, Cyclacel Pharmaceuticals beat earnings estimates, reporting EPS of -$0.47 on estimates of -$0.66. The stock fell by -1.26% the day after the last earnings release.

Year-to-date, CYCC stock has fallen by -9.86%.

About Cyclacel Pharmaceuticals

Cyclacel Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. It uses cell cycle, transcriptional regulation and DNA damage response biology to develop innovative, targeted medicines for cancer and other proliferative diseases. The company builds a diversified biopharmaceutical business, which is focused in hematology and oncology based on a pipeline of novel drug candidates. Its products include CYC065, seliciclib, and sapacitabine. The company was founded by Ronald J. Berenson, David Philip Lane, and David Glover on August 13, 1996 and is headquartered in Berkeley Heights, NJ.

Stay up-to-date on earnings this week, with TipRanks’ Earnings Calendar.

Tags: ,